Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Rating of “Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $132.86.

LNTH has been the topic of several research analyst reports. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th.

Lantheus Price Performance

Shares of Lantheus stock opened at $98.17 on Wednesday. Lantheus has a one year low of $56.44 and a one year high of $126.89. The stock’s 50-day moving average is $89.97 and its 200 day moving average is $96.73. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of 16.33 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. On average, sell-side analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Activity

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus in the third quarter valued at approximately $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus during the fourth quarter valued at approximately $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus during the fourth quarter valued at approximately $37,000. UMB Bank n.a. increased its position in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares during the last quarter. Finally, RiverPark Advisors LLC purchased a new stake in shares of Lantheus during the third quarter valued at approximately $74,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.